Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Article from MarketBeat 3 Undervalued Names Too Cheap to IgnoreReported by Nathan Reiff. Published: 3/7/2026. 
Key Points - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
- Special Report: [Sponsorship-Ad-6-Format3]
Highly publicized growth trajectories of some of the biggest companies out there may make 2026 seem like a poor time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below represent potential value plays, with metrics that are historically low and/or competitive relative to peers or the broader market. They also offer added benefits such as compelling dividends or promising new product developments. While clear value opportunities can be harder to find when many growth names have regained investor attention—and some apparent bargains hide deteriorating operations—well-established, stable names can still merit consideration. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works Currently, $2 TRILLION worth of transactions go through the traditional network every single day. But soon, it will be funneled through the new network that the Federal Reserve has built, operates and can see in real time.
That's the part buried in the Federal Reserve Docket No. OP-1670.
In fact, on page 84 of the 93-page document, they admit that it will make it easier to track the spending of Americans. That's why I've put together 4 steps to "Fed proof" your savings Although shares have climbed more than 28% in the last year, bringing its market capitalization to nearly $300 billion, biopharma giant Merck & Co. Inc. (NYSE: MRK) still carries a price-to-earnings (P/E) ratio of 16.45, well below the medical-industry average of roughly 27. Analysts expect continued growth: the company is projected to see earnings rise by nearly 10% in the coming year and has about 5% additional upside in the near term. Driving Merck's momentum is its pembrolizumab cancer drug, Keytruda, which was approved for subcutaneous injection by the European Commission in late 2025 and generated roughly $8.4 billion in sales in Q4 2025, an increase of almost 7% year-over-year. Keytruda also shows promise for ovarian cancer indications, potentially expanding its patient base. These factors should help Merck build revenue as Keytruda approaches patent expiration in 2028. Merck's portfolio is also broadening: the company recently announced phase 3 results for clesrovimab-cfor (Enflonsia), a treatment for RSV in young children. At the same time, Merck is restructuring—splitting its human health business into two units—to better position the company to expand non-oncology sales as it prepares for Keytruda's patent loss. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell's (NASDAQ: CPB) shares have fallen roughly 37% over the last year as the food-and-beverage staple faced pressure from tariffs and inflation. In Q1 fiscal 2026, which ended Nov. 2, 2025, the company recorded modest year-over-year declines in organic net sales and consumption, with adjusted earnings per share (EPS) down about 13%. The company has yet to see meaningful margin improvement despite cost-saving initiatives. Near-term guidance remains weak, so the outlook is likely to be challenging for a while. That said, improvements in supply-chain execution and strong brand loyalty—especially for premium offerings—should help protect sales. Shifting tariff dynamics could also alleviate some cost pressures. Campbell's remains an attractive dividend stock, with a yield of 5.9%, although its payout ratio is fairly high at more than 80%. Its P/E ratio of about 13.5 is the lowest in roughly four years. Those factors may convince some investors that the stock is worth considering despite Wall Street caution. A Recent US Foods Rally May Continue; Bottom-Line Growth Remains in Place Foodservice distribution leader US Foods (NYSE: USFD) has moved in the opposite direction from Campbell's—shares climbed about 33% over the past year. Despite that rally, its P/E ratio of 31.6 remains reasonable relative to the broader market. On fundamentals, US Foods is making progress: the company reported improving profitability in the latest quarter and full-year adjusted EBITDA that rose about 11% year-over-year. Better inventory management and cost-of-goods savings are helping the firm regain momentum. With a $4 billion capital deployment plan, US Foods is positioned to sustain revenue growth and further expand adjusted EBITDA. Analysts rate USFD a Moderate Buy based on 11 Buys and 2 Holds, implying roughly 15% upside potential.
| 
